Pirprofen

Pirprofen is a Non-Steroidal anti-inflammatory Drug

Pirprofen is used in the treatment Osteoarthritis, Rheumatoid arthritis.

Pirprofen shows common side effects like GI disturbances, peptic ulcer, headache, dizziness, blurred vision, tinnitus, skin rashes and pruritus. Hematological changes and photosensitivity.

Pirprofen is available in tablets.

Pirprofen is available in India, Germany, Canada, France, USA.

Pirprofen is available in the form of tablets.

Pirprofen is used in the treatment Osteoarthritis, Rheumatoid arthritis.

Pirprofen is a nonsteroidal anti-inflammatory drug used in musculoskeletal and joint disorders.

Pirprofen is approved for use in the following clinical indications

Osteoarthritis, Rheumatoid arthritis.

Osteoarthritis, Rheumatoid arthritis

Adult: 600-800 mg daily.

Pirprofen is available in the form of tablets, capsules, and suspension.

Take after eating and with a full glass of water to decrease gastric upset.

Increased risk of hyperkalemia when used with ACE inhibitors and potassium-sparing diuretics. Convulsions may occur when used with quinolones. Effects of phenytoin and sulfonylureas may be enhanced. Antihypertensive effects of ACE inhibitors, β-blockers and diuretics may be reduced. Increased risk of GI bleeding and ulceration when used with corticosteroids, SSRIs or antiplatelet agents. Increased risk of hepatotoxicity when used with zidovudine. ACE inhibitors, ciclosporin, tacrolimus or diuretics may increase nephrotoxicity.

The common side effects of Pirprofen include the following :

GI disturbances, peptic ulcer, headache, dizziness, blurred vision, tinnitus, skin rashes and pruritus. Hematological changes and photosensitivity.

• Pharmacodynamics

In experimental animal models, pirprofen has been shown to possess anti-inflammatory, analgesic and antipyretic activities similar to those of several other non-steroidal anti-inflammatory drugs commonly used in the treatment of rheumatic conditions. The ulcerogenic activity of pirprofen in animals appears similar to that of diclofenac, flurbiprofen and indomethacin. The relative gastrointestinal toxicity compared with other non-steroidal anti-inflammatory drugs needs to be investigated further in animals and human subjects. Pirprofen inhibits the secondary phase of platelet aggregation induced by collagen and arachidonic acid in vitro but does not influence ADP-induced primary platelet aggregation in vitro or in vivo. Unlike aspirin whose effect is irreversible, pirprofen is a reversible inhibitor of prostaglandin synthetase in vitro and in vivo. It inhibits the cyclo-oxygenase but not the lipoxygenase pathway of arachidonic acid metabolism. Pirprofen is an inhibitor of leucocyte chemotaxis in vitro and in vivo in man, and it does not adversely affect cartilage in animal models of degenerative joint disease unlike certain other non-steroidal anti-inflammatory drugs.

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1364710/
2. https://reference.medscape.com/drug/colestid-Pirprofen -342452
3. https://go.drugbank.com/drugs/DB00375
4. https://www.sciencedirect.com/topics/medicine-and-dentistry/Pirprofen
5. https://europepmc.org/article/med/6988203